SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Alignment Healthcare, Inc. (ALHC) has a negative trailing P/E of -5,780.2, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 161.8 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -0.02%, forward earnings yield 0.62%. PEG 1.80.
Criteria proven by this page:
- VALUE (75/100, Pass) — analyst target implies upside (+15.1%).
- Forward P/E 161.8 — analysts expect a return to profitability with estimated EPS of $0.13 for FY2026.
- PEG Ratio 1.80 — between 1.0–2.0 indicates moderate valuation relative to growth.
- Trailing Earnings Yield -0.02% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 0.62% as earnings recover.
- Analyst consensus target $24.50 (+15.1% upside) — significant upside potential according to Wall Street analysts.
Overall SharesGrow Score: 53/100 with 3/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
75/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
33/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — ALHC
Valuation Multiples
P/E (TTM)-5,780.2
Forward P/E161.8
PEG Ratio1.80
Forward PEG1.80
P/B Ratio23.34
P/S Ratio1.09
EV/EBITDA90.1
Per Share Data
EPS (TTM)$0.00
Forward EPS (Est.)$0.13
Book Value / Share$0.91
Revenue / Share$19.94
FCF / Share$0.62
Yields & Fair Value
Earnings Yield-0.02%
Forward Earnings Yield0.62%
Dividend Yield0.00%
SharesGrow IV$658.70 (+2995.4%)
Analyst Target$24.50 (+15.1%)
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2019 |
-58.9 |
0.00 |
-33.46 |
3.48 |
- |
| 2020 |
-141.4 |
2.41 |
105.90 |
3.38 |
- |
| 2021 |
-12.4 |
-0.01 |
7.90 |
2.07 |
- |
| 2022 |
-14.3 |
0.52 |
8.95 |
1.49 |
- |
| 2023 |
-10.8 |
2.25 |
10.22 |
0.88 |
- |
| 2024 |
-16.8 |
1.10 |
21.50 |
0.79 |
- |
| 2025 |
-5,401.4 |
54.31 |
21.81 |
0.99 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2019 |
$-0.32 |
$756.96M |
$-59.28M |
-7.8% |
| 2020 |
$-0.21 |
$959.22M |
$-39.13M |
-4.1% |
| 2021 |
$-1.24 |
$1.17B |
$-212.96M |
-18.2% |
| 2022 |
$-0.83 |
$1.43B |
$-149.64M |
-10.4% |
| 2023 |
$-0.79 |
$1.82B |
$-148.02M |
-8.1% |
| 2024 |
$-0.67 |
$2.7B |
$-128.04M |
-4.7% |
| 2025 |
$0.00 |
$3.95B |
$-724K |
-0% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.13 |
$0.04 – $0.36 |
$5.18B |
$5.12B – $5.2B |
6 |
| 2027 |
$0.37 |
$0.24 – $0.59 |
$6.48B |
$6.16B – $6.89B |
6 |
| 2028 |
$0.73 |
$0.52 – $0.86 |
$7.99B |
$7.99B – $7.99B |
5 |
| 2029 |
$1.29 |
$1.24 – $1.36 |
$10.53B |
$10.18B – $10.94B |
1 |
| 2030 |
$1.71 |
$1.64 – $1.80 |
$13.89B |
$13.44B – $14.44B |
1 |
